Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intrathecally Administered LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis

NCT07660614 is registered in ClinicalTrials.gov with Leal Therapeutics, Inc as lead sponsor.

NCT NCT07660614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07660614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intrathecally Administered LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
Lead sponsor
Leal Therapeutics, Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 29, 2026
Completion date
June 30, 2031
Enrollment
56 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis